Efgartigimod Access Program for Generalized Myasthenia Gravis

Sponsor: argenx

Expanded Access
Approved for Marketing
Sponsor score: 40
Inactive

ClinicalTrials ID:NCT04777734

This program provides access to the medication efgartigimod for patients with generalized myasthenia gravis (gMG) who cannot join a clinical trial. It is available to those who need treatment before the drug is officially approved.

Patient Parameters

Program Overview

This program is designed to help patients with generalized myasthenia gravis (gMG) who are not part of a clinical trial get access to efgartigimod. The goal is to offer treatment to those who are not eligible for ongoing trials, allowing them to receive the medication before it is officially approved. There are specific protocols for different countries, and individual access is also available. However, recruitment for the treatment protocol in the US is currently closed.

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years or older.
  • Diagnosed with myasthenia gravis (MG) with generalized muscle weakness, whether or not specific antibodies are present.
  • Must have been vaccinated against COVID-19 or tested negative for COVID-19 within two weeks before joining.
  • Must have a documented IgG level greater than 6 g/L within one month before joining.
  • Must agree to use contraception as per local guidelines:
    • Men must use contraception and not donate sperm during the program.
    • Women of childbearing age must use effective contraception and have a negative pregnancy test before starting.
  • Must sign a consent form agreeing to follow the program's rules.
  • If there's a history of hepatitis B, C, or HIV, must have a negative test for active infection.

Exclusion Criteria

  • Have an uncontrolled or active infection at the time of joining.
  • Have another autoimmune disease that could affect the assessment of gMG symptoms or increase risk.
  • Have had cancer unless it was treated and has not returned for at least 3 years, except for certain skin cancers or early-stage prostate cancer.
  • Have other serious health conditions, recent major surgery, or any condition that could increase risk.
  • Have received a live vaccine in the month before joining.
  • Are pregnant, breastfeeding, or planning to become pregnant during or shortly after the program.
  • Are a sexually active male not using contraception during the program and for 90 days after, or planning to donate sperm during this time.
  • Have received rituximab within 6 months before starting efgartigimod.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.